Literature DB >> 2744086

Effect of acute and chronic MDL 73,147EF, a 5-HT3 receptor antagonist, on A9 and A10 dopamine neurons.

S M Sorensen1, T M Humphreys, M G Palfreyman.   

Abstract

MDL 73,147EF (1H-indole-3-carboxylic acid-trans-octahydro-3-oxo-2,6- methano-2H-quinolizin-8-yl-ester methanesulphonate) is a potent and selective 5-HT3 receptor antagonist (pA2 9.8, rabbit heart; pIC50 less than 5, D-2 receptor). The effects of acutely and chronically administered haloperidol and MDL 73,147EF were compared in an electrophysiologic model for antipsychotic activity. Haloperidol, but not MDL 73,147EF, given acutely increased the number of active dopamine neurons in the substantia nigra (A9). Both haloperidol and MDL 73,147EF, given chronically, decreased the number of active ventral tegmental dopamine neurons and the number of active A9 dopamine neurons. The results indicate that MDL 73,147EF may prove useful as an antipsychotic with a unique mechanism of action.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2744086     DOI: 10.1016/0014-2999(89)90402-0

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  13 in total

1.  Involvement of 5-HT(3) receptors in the nucleus accumbens in the potentiation of cocaine-induced behaviours in the rat.

Authors:  S Herges; D A Taylor
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

Review 2.  Modulation of ligand-gated ion channels by antidepressants and antipsychotics.

Authors:  Gerhard Rammes; Rainer Rupprecht
Journal:  Mol Neurobiol       Date:  2007-04       Impact factor: 5.590

Review 3.  The non-antiemetic uses of serotonin 5-HT3 receptor antagonists. Clinical pharmacology and therapeutic applications.

Authors:  A J Greenshaw; P H Silverstone
Journal:  Drugs       Date:  1997-01       Impact factor: 9.546

Review 4.  Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission.

Authors:  K D Alex; E A Pehek
Journal:  Pharmacol Ther       Date:  2006-10-17       Impact factor: 12.310

5.  Serotonergic modulation of striatal D2 dopamine receptor binding in humans measured with positron emission tomography.

Authors:  J Tiihonen; M Kuoppamäki; K Någren; J Bergman; E Eronen; E Syvälahti; J Hietala
Journal:  Psychopharmacology (Berl)       Date:  1996-08       Impact factor: 4.530

6.  Electrophysiological, biochemical and behavioral evidence for 5-HT2 and 5-HT3 mediated control of dopaminergic function.

Authors:  M G Palfreyman; C J Schmidt; S M Sorensen; M W Dudley; J H Kehne; P Moser; M W Gittos; A A Carr
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

Review 7.  Cortical regulation of subcortical dopamine systems and its possible relevance to schizophrenia.

Authors:  A A Grace
Journal:  J Neural Transm Gen Sect       Date:  1993

8.  Role of 5-HT3 receptors in basal and K(+)-evoked dopamine release from rat olfactory tubercle and striatal slices.

Authors:  A Zazpe; I Artaiz; J Del Río
Journal:  Br J Pharmacol       Date:  1994-11       Impact factor: 8.739

Review 9.  Interactions between 5-HT3 receptors and cerebral dopamine function: implications for the treatment of schizophrenia and psychoactive substance abuse.

Authors:  R M Hagan; G J Kilpatrick; M B Tyers
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

Review 10.  The role of 5-HT3 receptors in drug abuse and as a target for pharmacotherapy.

Authors:  E A Engleman; Z A Rodd; R L Bell; J M Murphy
Journal:  CNS Neurol Disord Drug Targets       Date:  2008-11       Impact factor: 4.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.